Redx Pharma Unveils Promising Data for Zamaporvint in GI Cancer Trials

Redx Pharma has presented encouraging Phase 2 trial results for its investigational drug, zamaporvint (RXC004), at the ESMO GI Congress. Designed for genetically-selected MSS mCRC patients, zamaporvint demonstrated partial responses in about 30% of cases when combined with anti-PD-1 therapy, notably outperforming existing standards where anti-PD-1 alone fails.

The clinical-stage biotech company highlighted zamaporvint's potential in treating hard-to-treat gastrointestinal cancers by focusing on Wnt-ligand dependency in tumors. The study showed a disease control rate of 57%, offering a new avenue for patients with limited treatment options.

Zamaporvint's tolerable safety profile and observed efficacy, particularly in genetically-selected patient subsets, underscore its potential in combination therapies. These findings pave the way for its further development in this patient group, with Redx seeking partnerships to advance clinical trials.